Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Sees Significant Decline in Short Interest

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) was the target of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 9,900 shares, a decline of 27.2% from the January 15th total of 13,600 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily volume of 34,700 shares, the days-to-cover ratio is currently 0.3 days.

Lakeshore Biopharma Stock Performance

NASDAQ LSB traded down $0.01 on Friday, hitting $2.40. The stock had a trading volume of 3,906 shares, compared to its average volume of 8,274. The business’s fifty day moving average price is $2.78 and its 200 day moving average price is $3.70. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.17 and a quick ratio of 0.90. Lakeshore Biopharma has a 52-week low of $1.88 and a 52-week high of $11.20.

Institutional Investors Weigh In On Lakeshore Biopharma

A number of large investors have recently made changes to their positions in the stock. FMR LLC purchased a new stake in shares of Lakeshore Biopharma during the 3rd quarter worth about $803,000. Hhlr Advisors LTD. purchased a new stake in shares of Lakeshore Biopharma during the 3rd quarter worth about $513,000. Finally, Barclays PLC purchased a new stake in shares of Lakeshore Biopharma during the 3rd quarter worth about $169,000. 52.64% of the stock is owned by hedge funds and other institutional investors.

Lakeshore Biopharma Company Profile

LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.